Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2011

01-02-2011 | Research Article

DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy

Authors: Hyunki Kim, Karri D. Folks, Lingling Guo, Cecil R. Stockard, Naomi S. Fineberg, William E. Grizzle, James F. George, Donald J. Buchsbaum, Desiree E. Morgan, Kurt R. Zinn

Published in: Molecular Imaging and Biology | Issue 1/2011

Login to get access

Abstract

Purpose

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts.

Procedures

Groups 1–4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining.

Results

DCE-MRI measured a significant K trans change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K trans changes followed quadratic polynomial curves.

Conclusion

DCE-MRI detected significantly lower K trans levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
Appendix
Available only for authorised users
Literature
1.
Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821CrossRefPubMed
2.
Hylander BL, Pitoniak R, Penetrante RB et al (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22CrossRefPubMed
3.
Jo M, Kim TH, Seol DW et al (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564–567CrossRefPubMed
4.
Emery JG, McDonnell P, Burke MB et al (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–14367CrossRefPubMed
5.
Ichikawa K, Liu W, Zhao L et al (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954–960CrossRefPubMed
6.
Forero-Torres A, Shah J, Wood T et al (2009) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13–19CrossRef
7.
Buchsbaum DJ, Zhou T, Grizzle WE et al (2003) Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731–3741PubMed
8.
Evelhoch JL, Gillies RJ, Karczmar GS et al (2000) Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2:152–165CrossRefPubMed
9.
Cheung YC, Chen SC, Su MY et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78:51–58CrossRefPubMed
10.
Martincich L, Montemurro F, De Rosa G et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83:67–76CrossRefPubMed
11.
Wedam SB, Low JA, Yang SX et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777CrossRefPubMed
12.
Liu G, Rugo HS, Wilding G et al (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23:5464–5473CrossRefPubMed
13.
Spinosa DJ, Kaufmann JA, Hartwell GD (2002) Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography. Radiology 223:319–325CrossRefPubMed
14.
Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMed
15.
Kim YR, Rebro KJ, Schmainda KM (2002) Water exchange and inflow affect the accuracy of T1-GRE blood volume measurements: implications for the evaluation of tumor angiogenesis. Magn Reson Med 47:1110–1120CrossRefPubMed
16.
Yankeelov TE, Luci JJ, Lepage M et al (2005) Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 23:519–529CrossRefPubMed
17.
Yankeelov TE, Cron GO, Addison CL et al (2007) Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magn Reson Med 57:353–361CrossRefPubMed
18.
Kim H, Morgan DE, Zeng H et al (2008) Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 248:844–851CrossRefPubMed
19.
Sternberg SR (1983) Biomedical image processing. IEEE Computer 16:22–34
20.
Hertzog C, Rovine M (1985) Repeated-measures analysis of variance in developmental research: selected issues. Child Dev 56:787–809CrossRefPubMed
21.
Maxwell SE (1980) Pairwise multiple comparisons in repeated measures designs. J Educ Behav Stat 5:269–287CrossRef
22.
Neter J, Kutner MH, Nachtsheim JC, Wasserman W (1996) Applied linear statistical models. McGraw-Hill, Columbus
23.
Sokal RR, Rohlf FJ (1995) Biometry: the principles and practice of statistics in biological research. Freeman, New York
24.
Rodgers JL, Nicewander WA (1988) Thirteen ways to look at the correlation coefficient. Am Stat 42:59–66CrossRef
25.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
26.
Wosik K, Biernacki K, Khouzam MP, Prat A (2007) Death receptor expression and function at the human blood brain barrier. J Neurol Sci 259:53–60CrossRefPubMed
27.
Su MY, Baik HM, Yu HJ, Chen JH, Mehta RS, Nalcioglu O (2006) Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Technol Cancer Res Treat 5:401–410PubMed
28.
Morse DL, Raghunand N, Sadarangani P et al (2007) Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 58:270–280CrossRefPubMed
29.
Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA (2004) Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 19:68–75CrossRefPubMed
30.
Momiyama N, Ishikawa T, Ichikawa Y, Shimada H, Katayama A, Ozawa Y (2007) [Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer]. Nippon Rinsho 65 Suppl 6:385–388PubMed
31.
Kiessling F, Farhan N, Lichy MP et al (2004) Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 6:213–223CrossRefPubMed
32.
Wilmes LJ, Pallavicini MG, Fleming LM et al (2007) AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25:319–327CrossRefPubMed
33.
Grubbs CJ, Hill DL, Bland KI et al (2003) 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett 201:17–24CrossRefPubMed
34.
Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802–820CrossRefPubMed
35.
36.
McLachlan SJ, Eaton S, De Simone DN (1992) Pharmacokinetic behavior of gadoteridol injection. Invest Radiol 27 Suppl 1:S12–S15PubMed
37.
Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR (2007) High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99 m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 6:866–875CrossRefPubMed
38.
Niermann KJ, Fleischer AC, Huamani J et al (2007) Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26:749–756PubMed
39.
Carano RA, Ross AL, Ross J et al (2004) Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med 51:542–551CrossRefPubMed
Metadata
Title
DCE-MRI Detects Early Vascular Response in Breast Tumor Xenografts Following Anti-DR5 Therapy
Authors
Hyunki Kim
Karri D. Folks
Lingling Guo
Cecil R. Stockard
Naomi S. Fineberg
William E. Grizzle
James F. George
Donald J. Buchsbaum
Desiree E. Morgan
Kurt R. Zinn
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 1/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-010-0320-2

Other articles of this Issue 1/2011

Molecular Imaging and Biology 1/2011 Go to the issue

Research Article

Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction

Research Article

Integrated PET/CT Fusion Imaging and Endoscopic Ultrasound in the Pre-operative Staging and Evaluation of Esophageal Cancer

Research Article

Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry

Research Article

Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers

Research Article

Comparative Assessment of Energy-Mapping Approaches in CT-Based Attenuation Correction for PET

Research Article

Lectin–Gd-Loaded Chitosan Hydrogel Nanoparticles: A New Biospecific Contrast Agent for MRI